UBS Asset Management Americas Inc. Has $19.85 Million Stake in China Biologic Products, Inc. (CBPO)

UBS Asset Management Americas Inc. raised its stake in China Biologic Products, Inc. (NASDAQ:CBPO) by 9.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 198,220 shares of the biopharmaceutical company’s stock after buying an additional 16,933 shares during the period. UBS Asset Management Americas Inc.’s holdings in China Biologic Products were worth $19,848,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Pictet Asset Management Ltd. purchased a new position in shares of China Biologic Products during the first quarter worth approximately $1,762,000. Bank of New York Mellon Corp raised its position in shares of China Biologic Products by 5.9% in the first quarter. Bank of New York Mellon Corp now owns 563,527 shares of the biopharmaceutical company’s stock worth $56,426,000 after buying an additional 31,297 shares during the last quarter. Henderson Group PLC raised its position in shares of China Biologic Products by 9.3% in the first quarter. Henderson Group PLC now owns 188,585 shares of the biopharmaceutical company’s stock worth $18,877,000 after buying an additional 16,017 shares during the last quarter. First Trust Advisors LP raised its position in shares of China Biologic Products by 35.9% in the first quarter. First Trust Advisors LP now owns 11,561 shares of the biopharmaceutical company’s stock worth $1,158,000 after buying an additional 3,053 shares during the last quarter. Finally, Eqis Capital Management Inc. raised its position in shares of China Biologic Products by 51.3% in the first quarter. Eqis Capital Management Inc. now owns 3,220 shares of the biopharmaceutical company’s stock worth $322,000 after buying an additional 1,092 shares during the last quarter. Hedge funds and other institutional investors own 74.28% of the company’s stock.

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Shares of China Biologic Products, Inc. (CBPO) opened at 109.85 on Tuesday. The stock has a 50 day moving average price of $112.78 and a 200 day moving average price of $109.62. The company has a market capitalization of $2.99 billion, a price-to-earnings ratio of 28.45 and a beta of 1.73. China Biologic Products, Inc. has a 1-year low of $96.99 and a 1-year high of $137.38.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Mideast Time and is owned by of Mideast Time. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.mideasttime.com/ubs-asset-management-americas-inc-has-19-85-million-stake-in-china-biologic-products-inc-cbpo/1794689.html.

A number of equities analysts recently commented on the company. Jefferies Group LLC reissued a “buy” rating and set a $140.00 price target on shares of China Biologic Products in a research note on Monday, June 12th. Goldman Sachs Group, Inc. (The) assumed coverage on China Biologic Products in a research note on Tuesday, May 30th. They set a “neutral” rating for the company. Zacks Investment Research lowered China Biologic Products from a “hold” rating to a “sell” rating in a research note on Friday, May 5th. Finally, Morgan Stanley reissued an “overweight” rating and set a $135.00 price target on shares of China Biologic Products in a research note on Friday, March 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $132.00.

In other news, insider Zhijing Cbpo Liu sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $116.49, for a total value of $873,675.00. Following the completion of the sale, the insider now directly owns 10,969 shares in the company, valued at $1,277,778.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.73% of the stock is currently owned by insiders.

China Biologic Products Company Profile

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:CBPO”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding CBPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for China Biologic Products, Inc. (NASDAQ:CBPO).

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.